Effect of a 5-lipoxygenase Inhibitor and Leukotriene Antagonist (PF 5901) on Antigen-induced Airway Responses in Neonatally Immunized Rabbits

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1994 May 1

PMID 8032653

Citations 6

Authors

C M Herd

T S Shoupe

D A Burroughs

M Yeadon

C P Page

Affiliations

Soon will be listed here.

Abstract

1. The effect of a single intratracheal dose (10 mg) of PF 5901 (2-[3(1-hydroxyhexyl) phenoxymethyl] quinoline hydrochloride, a specific inhibitor of the 5-lipoxygenase pathway of arachidonic acid metabolism and a leukotriene D4 antagonist) on airway changes induced in response to Alternaria tenuis aerosol challenge was assessed in adult rabbits neonatally immunized. Leukotriene generation was determined in vivo by measuring leukotriene B4 (LTB4) levels in bronchoalveolar lavage (BAL) fluid and ex vivo by measuring calcium ionophore-stimulated production of LTB4 in whole blood. 2. While PF 5901 (10 mg) had no significant effect on the acute bronchoconstriction induced by antigen, this dose was sufficient to inhibit significantly the increase in airway responsiveness to inhaled histamine 24 h following antigen challenge (P < 0.05). 3. Total leucocyte infiltration into the airways induced by antigen, as assessed by bronchoalveolar lavage, was significantly inhibited by pretreatment with PF 5901 (10 mg). However, the pulmonary infiltration of neutrophils and eosinophils induced by antigen was unaltered by prior treatment with PF 5901 (10 mg). 4. PF 5901 (10 mg) had no effect on ex vivo LTB4 synthesis in whole blood. However, the antigen-induced increase in LTB4 levels in BAL 24 h following challenge was significantly inhibited (P < 0.05). 5. We suggest from the results of the present study that the antigen-induced airway hyperresponsiveness to inhaled histamine in immunized rabbits is mediated, at least in part, by products of the 5-lipoxygenase metabolic pathway, and is not dependent on the extent of eosinophil or neutrophil influx into the airway lumen.

Citing Articles

Asthma: The Use of Animal Models and Their Translational Utility.

Woodrow J, Sheats M, Cooper B, Bayless R Cells. 2023; 12(7).

PMID: 37048164 PMC: 10093022. DOI: 10.3390/cells12071091.

Lack of desensitization of the cough reflex in ovalbumin-sensitized rabbits during exercise.

Tiotiu A, Chenuel B, Foucaud L, Demoulin B, Demoulin-Alexikova S, Christov C PLoS One. 2017; 12(2):e0171862.

PMID: 28182749 PMC: 5300204. DOI: 10.1371/journal.pone.0171862.

The rabbit as a model for studying lung disease and stem cell therapy.

Kamaruzaman N, Kardia E, Kamaldin N, Latahir A, Yahaya B Biomed Res Int. 2013; 2013:691830.

PMID: 23653896 PMC: 3638694. DOI: 10.1155/2013/691830.

Effect of heparin on antigen-induced airway responses and pulmonary leukocyte accumulation in neonatally immunized rabbits.

Preuss J, Page C Br J Pharmacol. 2000; 129(8):1585-96.

PMID: 10780962 PMC: 1572004. DOI: 10.1038/sj.bjp.0703247.

Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits.

Gozzard N, Herd C, Blake S, Holbrook M, Hughes B, Higgs G Br J Pharmacol. 1996; 118(5):1201-8.

PMID: 8818344 PMC: 1909605. DOI: 10.1111/j.1476-5381.1996.tb15524.x.

References

Coyle A, Page C, Atkinson L, Sjoerdsma K, Touvay C, Metzger W . Modification of allergen-induced airway obstruction and airway hyperresponsiveness in an allergic rabbit model by the selective platelet-activating factor antagonist, BN 52021. J Allergy Clin Immunol. 1989; 84(6 Pt 1):960-7. DOI: 10.1016/0091-6749(89)90395-3. View

Minshall E, Riccio M, Herd C, DOUGLAS G, Seeds E, McKenniff M . A novel animal model for investigating persistent airway hyperresponsiveness. J Pharmacol Toxicol Methods. 1993; 30(4):177-88. DOI: 10.1016/1056-8719(93)90015-7. View

Dixon R, Diehl R, Opas E, Rands E, Vickers P, Evans J . Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990; 343(6255):282-4. DOI: 10.1038/343282a0. View

Sanjar S, Aoki S, Boubekeur K, Chapman I, Smith D, Kings M . Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: effect of anti-asthma drugs. Br J Pharmacol. 1990; 99(2):267-72. PMC: 1917376. DOI: 10.1111/j.1476-5381.1990.tb14692.x. View

Miadonna A, Tedeschi A, BRASCA C, Folco G, Sala A, Murphy R . Mediator release after endobronchial antigen challenge in patients with respiratory allergy. J Allergy Clin Immunol. 1990; 85(5):906-13. DOI: 10.1016/0091-6749(90)90076-g. View

Wenzel S, Larsen G, Johnston K, Voelkel N, Westcott J . Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 1990; 142(1):112-9. DOI: 10.1164/ajrccm/142.1.112. View

Coyle A, Page C, Atkinson L, Flanagan R, Metzger W . The requirement for platelets in allergen-induced late asthmatic airway obstruction. Eosinophil infiltration and heightened airway responsiveness in allergic rabbits. Am Rev Respir Dis. 1990; 142(3):587-93. DOI: 10.1164/ajrccm/142.3.587. View

Kings M, Chapman I, Kristersson A, Sanjar S, Morley J . Human recombinant lymphokines and cytokines induce pulmonary eosinophilia in the guinea pig which is inhibited by ketotifen and AH 21-132. Int Arch Allergy Appl Immunol. 1990; 91(4):354-61. DOI: 10.1159/000235141. View

Knapp H . Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990; 323(25):1745-8. DOI: 10.1056/NEJM199012203232506. View

10.

TAYLOR I, OShaughnessy K, Fuller R, Dollery C . Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991; 337(8743):690-4. DOI: 10.1016/0140-6736(91)90277-v. View

11.

Hui K, TAYLOR I, Taylor G, Rubin P, Kesterson J, Barnes N . Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 1991; 46(3):184-9. PMC: 463027. DOI: 10.1136/thx.46.3.184. View

12.

Evans J, Leville C, Mancini J, Prasit P, THERIEN M, Zamboni R . 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol. 1991; 40(1):22-7. View

13.

Matsuse T, Thomson R, Chen X, Salari H, Schellenberg R . Capsaicin inhibits airway hyperresponsiveness but not lipoxygenase activity or eosinophilia after repeated aerosolized antigen in guinea pigs. Am Rev Respir Dis. 1991; 144(2):368-72. DOI: 10.1164/ajrccm/144.2.368. View

14.

OHickey S, Hawksworth R, Fong C, Arm J, Spur B, Lee T . Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis. 1991; 144(5):1053-7. DOI: 10.1164/ajrccm/144.5.1053. View

15.

Ford-Hutchinson A . Inhibition of leukotriene biosynthesis. Ann N Y Acad Sci. 1991; 629:133-42. DOI: 10.1111/j.1749-6632.1991.tb37970.x. View

16.

Herd C, Shoupe T, Page C . Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAF-induced airway responses in neonatally immunized rabbits. Br J Pharmacol. 1992; 107(4):1108-15. PMC: 1907955. DOI: 10.1111/j.1476-5381.1992.tb13415.x. View

17.

Noonan T, Desai S . Effect of BI-L-239, A-64077 and MK-886 on leukotriene B4 synthesis by chopped guinea pig lung and on antigen-induced tracheal contraction in vitro. Prostaglandins. 1992; 44(6):543-54. DOI: 10.1016/0090-6980(92)90024-n. View

18.

Cockcroft D, Killian D, Mellon J, Hargreave F . Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 1977; 7(3):235-43. DOI: 10.1111/j.1365-2222.1977.tb01448.x. View

19.

Ford-Hutchinson A, Bray M, Doig M, Shipley M, Smith M . Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980; 286(5770):264-5. DOI: 10.1038/286264a0. View

20.

Peters S, MacGlashan Jr D, Siegel M, Lichtenstein L . The modulation of human basophil histamine release by products of the 5-lipoxygenase pathway. J Immunol. 1982; 129(2):797-803. View